
The International Conference on Systems Medicine, AI & Drug Repurposing
BerlinSeptember 23-25, 2026
Futurium
REGISTER NOW
Our poster collection
Fluency isn’t accuracy: Eliminating AI citation fabrication with Seraj, an agentic biomedical research platform
Manish Sarkar
MedInsights (FR)
Mechanism-guided feature selection in transcriptomic drug response prediction
Imane Wifak
Center for AI in Radiation Oncology (CH)
AI-Orchestrated Integration of Structural, Knowledge-Graph, Gene Expression, and Real-World Evidence for Drug Repurposing
YinHsong Hsu
Repurgenesis (TW)
Beyond Antibiotic Therapy: in silico identification of potential PqsR inhibitors in Pseudomonas aeruginosa
Mara Custódio
Polytechnic University of Guarda (PT)
Similar Kinases, Distinct Hits: In Silico Repurposing of FDA-Approved Drugs for ALK and ROS1
Maria Marques
Polytechnic University of Guarda (PT)
RePo_VR: An Immersive Virtual Reality Application for Molecular Docking Visualization in Drug Repurposing
António Costa
Polytechnic University of Guarda (PT)
Network and Co-Complex Representations Identify Distinct Components of the SynGAP Protein Environment
Helma Caune
Maastricht University (NL)
GNExT uncovers pharmacological targets from genome-wide association studies through network medicine integration
Markus List
Technical University of Munich (DE)
Network analysis of Charcot-Marie-Tooth Disease Type 1A prioritises a membrane-homeostasis module and KCNN4 as a candidate drug target
Julius A. L. Kötting
Maastricht University (NL)
A network medicine framework for mechanism-guided drug combinations in neurological disorders
Andrea Álvarez
Technical University of Madrid (ES)
Network-Based Prioritisation Identifies More Candidates Beyond a Phenotype-Based Comparator in Alzheimer’s Disease: A NeDRex/ REPO4EU Case Study
Ute Werner
Uniklinik Aachen (DE)
Network Medicine in Duchenne Muscular Dystrophy Generates a Mechanistic NOS–sGC-Targeted Drug-Repurposing Combination Hypothesis
Ceren Hangül
Akdeniz University (TR)
Perceived impact and actionability of barriers to drug repurposing: Insights from a multi-stakeholder policy survey
Kristóf Gyöngyösi
Semmelweis University (HU)
Clinical Trials in Drug Repurposing: An Ethics-by-Design Approach
Filipa Lopes
University of Porto (PT)
Mapping “Ethics by Design” and “Privacy by Design”: Implications for Precision Medicine and Drug Repurposing
Maria Strecht Almeida
University of Porto (PT)
Public Health Stakeholder Engagement in Drug Repurposing: Lessons Learned from RePo-SUDOE
João José Joaquim
Portuguese Society of Public Health (PT)
Developing an R Shiny Health Economic Model Tool to Support Early Decision-Making in Mechanism-Based Drug Repurposing
Teebah Abu-Zahra
Maastricht UMC+ (NL)

